CD8A and non-small cell lung carcinoma: Our work was performed by collecting 10127 CD8+ tumor‐infiltrating lymphocytes (TILs) from 12 NSCLC patients for single‐cell analysis (4 patients without anti‐PD‐1 neoadjuvant therapy [naïve], 4 in the major pathologic response [MPR] group after receiving anti‐PD‐1 therapy, and 4 patients that did not achieve major pathologic remission [Non‐MPR] after receiving anti‐PD‐1 therapy).